BioCentury | Aug 21, 2020
Product Development

Basket trials carry tumor-agnostic drug development forward

...1 ligand 1POLE – DNA-directed DNA polymerase εPOLD1 – DNA polymerase δ1...
BioCentury | Jun 17, 2020
Deals

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

...Inc. (NASDAQ:IDYA) announced a partnership covering three preclinical programs targeting the biosynthetic enzyme MAT2A, the DNA polymerase...
...1 early onset MAT2A - Methionine adenosyltransferase 2A PARP - Poly(ADP-ribose) polymerase POLQ - DNA-directed DNA polymerase...
BioCentury | May 28, 2020
Deals

In its first broad deal, Repare leads BMS deeper into synthetic lethality

...target of rapamycin DNA-PK - DNA-dependent protein kinase PARP - Poly(ADP-ribose) polymerase POLQ - DNA-directed DNA polymerase...
BioCentury | Apr 24, 2020
Emerging Company Profile

FoRx: A broader look at DNA damage repair

...early onset BRCA2 - Breast cancer 2 early onset PARP - Poly(ADP-ribose) polymerase POLD3 - DNA polymerase...
BioCentury | Sep 13, 2019
Tools & Techniques

Enzymes aim to beat chemistry by creating longer, speedier, cleaner DNA strands

...tests for the approach. The companies are developing different strategies to coax TDT, a template-independent DNA polymerase...
...to each oligo. Among companies developing enzyme technologies, the primary workhorse is TDT, a template-independent DNA polymerase...
BioCentury | Sep 4, 2019
Finance

Repare readies for clinic with Cowen-led $82M B round

...FRP1) - Ataxia telangiectasia and Rad3 related; CCNE1 (CCNE) - Cyclin E1; POLQ - DNA-directed DNA polymerase...
...Investments Repare Therapeutics Inc. Ataxia telangiectasia and Rad3 related (ATR) (FRP1) Ataxia telangiectasia mutated (ATM) Cyclin E1 (CCNE1) (CCNE) DNA-directed DNA polymerase...
BioCentury | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

...Bacteroides numbers. The company will present detailed trial data for the first-in-class antibiotic, a bacterial DNA polymerase...
...Feb. 26, 2020, respectively. Sandi Wong, Staff Writer ACX-362E (GLS-362E) bempedoic acid/ezetimibe Ilixadencel (intuvax) Acurx Pharmaceuticals LLC Esperion Therapeutics Inc. Immunicum AB Bacterial DNA polymerase...
BioCentury | Mar 15, 2019
Clinical News

ViiV planning submissions this year for two-drug HIV regimen

...Assistant Editor cabotegravir (GSK1265744, s/gsk1265744, s-1265744) Edurant, rilpivirine (TMC278) GlaxoSmithKline plc Johnson & Johnson Pfizer Inc. Shionogi & Co. Ltd. ViiV Healthcare Ltd. DNA polymerase HIV...
BioCentury | Jan 11, 2019
Emerging Company Profile

Artios: Probing DNA Damage

...Lynparza olaparib. KuDos was acquired by AstraZeneca plc in 2005. Artios’ lead program targets DNA-directed DNA polymerase...
...University Repare Therapeutics Inc. Tango Therapeutics Inc. Breast cancer 1 early onset (BRCA1) Breast cancer 2 early onset (BRCA2) DNA-directed DNA polymerase...
BioCentury | Nov 9, 2018
Company News

NICE recommends Jazz's Vyxeos for AML

...using CombiPlex technology. Jazz Pharmaceuticals plc (NASDAQ:JAZZ), Dublin, Ireland Business: Cancer Jaime De Leon Vyxeos (CPX-351) Jazz Pharmaceuticals plc DNA polymerase Topoisomerase...
Items per page:
1 - 10 of 359